CDEK
← All drugs Report issue

larazotide acetate

Peptideexperimental

Larazotide is a synthetic eight amino acid peptide that functions as a tight junction regulator and reverses leaky junctions to their normally closed state. It has been studied in people with coeliac disease. — Wikipedia

Clinical trial activity

8 trials · 4 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
6
Phase 3
0
Phase 4
0

Earliest trial started Jan 1, 2006 (NCT00386490)

Timeline

2000s

  1. Jan 1, 2006

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2007

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CC(=O)O.CC(C)C[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)CN)C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)NCC(=O)O)C(C)C
Mol. weight
785.9 g/mol
Lipinski Ro5
2 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • at1001
  • at-1001
  • at-1001
  • at-1001
  • at-1001
  • larazotide acetate
  • larazotide acetate
  • larazotide acetate
  • larazotide acetate
  • zot protein, vibrio cholerae (288-293)

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05747534Phase 2May 31, 2023Harvard University
NCT05022303Phase 2Oct 31, 2021Harvard University
NCT01396213Phase 2Oct 1, 2011Alba Therapeutics, Sponsor GmbH, Teva
NCT00889473Phase 2Apr 1, 2009Alba Therapeutics
NCT00620451Phase 2Feb 1, 2008Alba Therapeutics
NCT00492960Phase 2Aug 1, 2007Alba Therapeutics
NCT00386165Phase 1Jan 1, 2006Alba Therapeutics
NCT00386490Phase 1Jan 1, 2006Alba Therapeutics
Showing 8 of 8 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Alba TherapeuticsFor profit6622006
Harvard UniversityAcademic/Hospital2212021
Sponsor GmbHAcademic/Hospital1012011
TevaFor profit1012011
4 organizations
Page 1 / 1